Company Encyclopedia
View More
name
BIOHEART-B
02185.HK
Shanghai Bio-heart Biological Technology Co., Ltd. an interventional cardiovascular device company, engages in the research and development of therapies for unmet medical needs of patients in the People’s Republic of China. The company develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. Shanghai Bio-heart Biological Technology Co., Ltd.
131.24 B
02185.HKMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking23/26
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-14.88%E
    • Profit Margin-428.18%E
    • Gross Margin46.47%B
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY22.57%B
    • Total Assets YoY14.15%B
    • Net Assets YoY-10.67%D
  • Cash ScoreD
    • Cash Flow Margin-23.35%D
    • OCF YoY0.00%D
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreB
    • Gearing Ratio25.57%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BIOHEART-B: IBERIS® RDN system registered in the UK

    BIOHEART-B announced that its subsidiary Antong's Iberis® RDN system has been registered with the MHRA in the UK. This system is the only renal denervation product approved for use via the radial artery and femoral artery access globally. Antong has reached a strategic cooperation with Baisheng International Group, planning to promote this product in multiple regions, with the ultimate goal of providing outpatient RDN procedures for patients worldwide

    Zhitong·
    HK
    02185
    +1.95%
    Zhitong·
    HK
    02185
    +1.95%

    BIOHEART-B: The IBERIS® RDN system has completed market access and the first commercial procedure in Switzerland

    BIOHEART-B announced that its Iberis® RDN system has completed market access and the first commercial procedure in Switzerland, performed by the University Hospital of Basel, with no reported complications. This system is the only renal denervation product approved for use via the radial artery and femoral artery access globally, aimed at providing outpatient procedures for patients worldwide. Antu has reached a strategic cooperation with Baisheng International Group, covering multiple regions, including the European Union, Asia-Pacific, and Latin America

    Zhitong·
    HK
    02185
    +1.95%
    Zhitong·
    HK
    02185
    +1.95%

    BIOHEART-B's controlling shareholder Wang Li plans to increase his holdings in the company's H shares by no more than HKD 15 million

    BIOHEART-B's controlling shareholder Wang Li plans to increase the company's H shares through its wholly-owned Winning Powerful Limited within the next 12 months, with an increase amount not exceeding HKD 15 million. Wang Li is confident about the company's future development, and currently, Winning Powerful Limited holds 18.75% of the company's shares

    Zhitong·
    HK
    02185
    +1.95%
    Zhitong·
    HK
    02185
    +1.95%

    RAYS Capital Partners Limited increased its holdings of BIOHEART-B by 800,000 shares at a price of HKD 8.749 per share

    According to the latest information from the Hong Kong Stock Exchange, on October 17, RAYS Capital Partners Limited increased its holdings of BIOHEART-B by 800,000 shares, at a price of HKD 8.749 per share, for a total amount of HKD 6.9992 million. After the increase, the latest number of shares held is 11.8682 million, with a latest holding ratio of 5.03%

    Zhitong·
    HK
    02185
    +1.95%
    Zhitong·
    HK
    02185
    +1.95%

    Understanding the Market | BIOHEART-B Rises Over 13% Again, RDN Catalysts Frequent This Year, Institutions Say BIOHEART's Commercialization is About to Accelerate

    BIOHEART-B rose over 10% again, as of the time of writing, up 13.5%, priced at HKD 8.83, with a transaction volume of HKD 106 million. Huafu Securities released a research report stating that in March 2025, Boston Scientific will acquire SoniVie for a total price of USD 600 million, actively entering the RDN track; in August, the American College of Cardiology and the American Heart Association updated the hypertension treatment guidelines and included RDN in the guidelines with a Class IIb recommendation; the proposed national coverage decision for RDN released by the Centers for Medicare & Medicaid Services (CMS) in July, if approved, will significantly accelerate clinical promotion and application. The firm pointed out that percutaneous renal denervation (RDN) is a new device therapy for uncontrolled and resistant hypertension. According to Frost & Sullivan, the annual market size for RDN in China is expected to exceed RMB 10 billion by 2032. The firm noted that the BIOHEART Iberis RDN system is the only one in the world approved for dual access RDN via both the radial artery (TRA) and the femoral artery, with significant first-mover advantages. Domestically, it has formed a major strategic cooperation with Yuan Da Health and Blue Sail Bo Sheng in multiple countries and regions overseas; Germany and France have included Iberis RDN in their medical insurance, currently serving as a starting point for accelerating commercialization for BIOHEART

    Zhitong·
    HK
    02185
    +1.95%
    Zhitong·
    HK
    02185
    +1.95%
    © 2025 Longbridge｜Disclaimer